Determining the precise function of CB1R–CB2R heteromers and elucidating the way in which these receptors modify neuronal signaling in the GPi will pave the way for the discovery of specific drugs that may either reduce GPi overactivity in the parkinsonian state or provide more effective management of dyskinesia. This evidence concerns the gene CNR1 and Dyskinesia.